Shares of St. Jude Medical closed down more than 4% yesterday after the FDA ordered it to run a 3-year study of its recalled Riata defibrillator leads.
St. Jude Medical's (NYSE:STJ) shares dropped more than 4% yesterday after the FDA ordered the medical device company to run a 3-year surveillance program of its recalled Riata defibrillator leads, plus 3 other leads that are still on the market.
STJ shares closed at $36.87 yesterday afternoon, down 4.4% on the day, but opened up slightly at $37.31 this morning. The stock has hovered around that mark so far this morning on Wall Street, reaching $36.96 as of about 10 a.m.
Yesterday afternoon the FDA ordered St. Jude to launch the 3-year post-market review of the recalled Riata and Riata ST leads, as well as for its QuickFlex LV CRT, QuickSite LV CRT, Riata ST Optim and Durata leads.